Selexis CHO Cells in Suspension-1

Archives 2019

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

 

OCTOBER 17, 2019
3 min read

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Geneva, Switzerland, and Newark, CA, OCTOBER 17, 2019Selexis SA and Teneobio, Inc. announced today that they have...

Read More
SEPTEMBER 17, 2019
3 min read

Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform

Geneva, Switzerland, and Moscow, Russia, September 17, 2019Selexis SA and Generium JSC today announced that a sixth...

Read More
SEPTEMBER 5, 2019
4 min read

ZyVersa Therapeutics to Advance Development of Its Lead Inflammasome Inhibitor with Selexis and KBI Biopharma’s Integrated Development Platform

Geneva, Switzerland, and Durham, NC, September 5, 2019 – JSR Life Sciences Companies Selexis SA and KBI Biopharma, Inc....

Read More
JUNE 20, 2019
5 min read

Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing

Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications...

Read More
MAY 6, 2019
5 min read

Selexis to Present Data at ESACT 2019 from the SUREtechnology and Beacon® Optofluidic Collaboration

Research Cell Banks Produce Therapeutic Proteins in Just Eight Weeks as Validated in Oral Presentation on Integration...

Read More
APRIL 9, 2019
4 min read

Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform

Geneva, Switzerland, and Moscow, Russia, April 9, 2019Selexis SA and Generium JSC today announced that a fifth...

Read More
APRIL 8, 2019
3 min read

Selexis Earns Spot Among the “Best Workplaces in Switzerland” for Second Consecutive Year

Geneva, Switzerland, APRIL 8, 2019Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
MARCH 28, 2019
3 min read

Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines

Yemi Onakunle, PhD, MBA, and Marco Bocci, PhD, DPharm, Promoted to Senior Vice Presidents of Licensing and Business...

Read More
FEBRUARY 26, 2019
4 min read

Selexis SA and Turgut Pharmaceuticals Expand Biosimilar Development Relationship by Signing Two Commercial License Agreements

Under the New CLAs, Selexis Will Help Advance Turgut’s Pipeline of Biosimilar Products in Oncology 

Geneva,...

Read More
JANUARY 9, 2019
3 min read

Selexis Expands Strategic Immuno-Oncology Alliance with Agenus

Agenus to Leverage Selexis’ SUREtechnology Platform™ to Progress its Unique Portfolio of Next-Generation Antibody...

Read More
JANUARY 4, 2019
4 min read

Selexis SA to Participate at Several Upcoming Industry Conferences

Geneva, Switzerland, January 4, 2019Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More